Stockscreener 앱 받기
7.31
0.14%
0.010
시간 외 거래:
7.39
0.08
+1.09%
Lipocine Inc 주식(LPCN)의 최신 뉴스
Lipocine Announces 2025 Financial Results and Progress on Postpartum Depression, Epilepsy, and Obesity Drug Pipeline - Minichart
Lipocine Inc. 2025 Annual Report: Innovative Oral Drug Delivery, CNS & Metabolic Pipeline, and R&D Highlights - Minichart
Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 - PR Newswire
Lipocine Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Lipocine 2025 Financial Results: Q4 & Annual PerformanceNews and Statistics - IndexBox
Lipocine: Fourth Quarter Financial Results Overview - Bitget
Lipocine: Q4 Earnings Snapshot - Barchart
Lipocine (NASDAQ: LPCN) 2025 revenue falls to $2M with $9.6M loss - Stock Titan
Lipocine 10-K: Revenue $2.0M, EPS (Basic) $(1.77) - TradingView
Lipocine Inc expected to post a loss of 61 cents a shareEarnings Preview - TradingView
Is Lipocine Inc affected by consumer sentiment2026 Performance Recap & Weekly Setup with High ROI Potential - baoquankhu1.vn
AI Stocks: Will Lipocine Inc benefit from rate cuts2025 Support & Resistance & Daily Profit Maximizing Tips - baoquankhu1.vn
Lipocine Stock Quote, Share Price, News and Analysis - Longbridge
Lipocine Files Prospectus to Enable $50M Stock Offering - The Globe and Mail
Lipocine (LPCN) Expected to Announce Earnings on Thursday - Defense World
Lipocine (LPCN) establishes $50M at-the-market common stock sales plan - Stock Titan
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) - Nasdaq
Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock? - Yahoo Finance
Lipocine Files For Common Stock Offering Of Up To $50 MillionSEC Filing - TradingView
LivePerson (NASDAQ: LPCN) increases ATM sales capacity to $50M - Stock Titan
Lipocine (LPCN) Jumps 5.5%: Does the Stock Have More Room to Grow? - Bitget
ETF Watch: Is Lipocine Inc a turnaround storyTreasury Yields & Daily Momentum Trading Reports - baoquankhu1.vn
Can Lipocine Inc. stock beat market expectations this quarterTreasury Yields & Short-Term High Return Ideas - mfd.ru
Lipocine completes patient visits in phase 3 trial for PPD treatment - Investing.com Australia
Lipocine completes patient visits in phase 3 trial for PPD treatment By Investing.com - Investing.com South Africa
Lipocine Completes Phase 3 Trial for Postpartum Depression - TipRanks
Lipocine (NASDAQ: LPCN) files updated corporate investor presentation - Stock Titan
Is Lipocine Inc. stock a buy on dips2025 Key Lessons & Proven Capital Preservation Tips - mfd.ru
Is Lipocine Inc. a potential multi baggerMarket Volume Summary & Low Drawdown Momentum Ideas - mfd.ru
Lipocine Announces Late Breaking Oral Presentation of Data from - GuruFocus
Buy Rating Maintained on Lipocine Inc. (LPCN) as Target Climbs to $15 - Finviz
Does Lipocine Inc. stock have upside surprise potential2025 Stock Rankings & Long Hold Capital Preservation Tips - mfd.ru
Why Lipocine Inc. stock is favored by top institutionsJuly 2025 WrapUp & Smart Allocation Stock Reports - mfd.ru
S P Trends: Does Lipocine Inc offer margin of safetyMarket Activity Summary & Short-Term High Return Ideas - baoquankhu1.vn
Lipocine Announces Positive Interim Results for PPD Trial - MSN
Lipocine (LPCN) Price Target Increased by 58.18% to 11.09 - Nasdaq
Market Moves: Can Lipocine Inc ride the EV waveJuly 2025 News Drivers & Precise Swing Trade Alerts - baoquankhu1.vn
EV Market: Is Lipocine Inc a cyclical or defensive stockPortfolio Value Report & Real-Time Buy Signal Alerts - baoquankhu1.vn
H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress By Investing.com - Investing.com South Africa
H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress - Investing.com India
Lipocine completes enrollment in phase 3 trial for PPD treatment By Investing.com - Investing.com South Africa
Lipocine Completes Phase 3 Enrollment for Postpartum Depression Drug - TipRanks
Lipocine Inc Completes Enrollment in Phase 3 Trial for PPD Treatment - TradingView
Lipocine completes enrollment in phase 3 trial for PPD treatment - Investing.com
At-home postpartum depression drug from Lipocine tested in 90 women - Stock Titan
CEO Moves: Can Lipocine Inc ride the EV waveJuly 2025 Sector Moves & Fast Gaining Stock Reports - baoquankhu1.vn
Performance Recap: What is TREEs TAM Total Addressable MarketWeekly Market Outlook & Weekly High Return Opportunities - baoquankhu1.vn
LPCN 1154 for postpartum depression continues clinical process after safety review - Contemporary OB/GYN
1.20%
0.06%
자본화:
|
볼륨(24시간):